Louisbourg Investments Inc. Has $2.33 Million Stock Position in Johnson & Johnson $JNJ

Louisbourg Investments Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 52.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,986 shares of the company’s stock after selling 11,030 shares during the quarter. Louisbourg Investments Inc.’s holdings in Johnson & Johnson were worth $2,333,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Auto Owners Insurance Co grew its stake in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth approximately $6,924,523,000. Capital World Investors acquired a new position in Johnson & Johnson during the 4th quarter worth $2,005,942,000. Diamant Asset Management Inc. lifted its holdings in Johnson & Johnson by 24,436.5% during the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after buying an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,972 shares of company stock valued at $12,295,205 in the last ninety days. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research note on Monday, August 3rd. TD Cowen raised their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Morgan Stanley lifted their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Argus set a $300.00 price objective on Johnson & Johnson in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $268.22.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $262.43 on Tuesday. The firm has a fifty day moving average of $252.52 and a two-hundred day moving average of $241.60. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $632.43 billion, a price-to-earnings ratio of 30.41, a PEG ratio of 2.48 and a beta of 0.24. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $274.90.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the company earned $2.77 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.